Taat Lifestyle & Wellness - CEO, Setti Coscarella
CEO, Setti Coscarella
Source: Tabacco Reporter
  • TAAT (TAAT) receives its first national mainstream media coverage in the US with an article published by Forbes profiling the company
  • The article details the value proposition of TAAT™ as an alternative to tobacco cigarettes due to its inherently non-addictive properties
  • TAAT™ Chief Executive Officer Setti Coscarella shares his professional background and journey to his current role at the company
  • The company will be hosting a live Q&A session with Mr. Coscarella on a Facebook Live stream at 9:15 am PST / 12:15 pm EST on Thursday, February 4
  • TAAT (TAAT) is up 6.54 per cent, trading at C$3.42 at 4 pm EST

TAAT (TAAT) receives its first national mainstream media coverage in the United States.

In addition to sharing his professional background with Forbes contributor Amanda Siebert, TAAT™ Chief Executive Officer Setti Coscarella, discusses TAAT’s partnership with packaged goods sales agency CROSSMARK.

Mr. Coscarella also details the value proposition of TAAT™ as an alternative to tobacco cigarettes and explains the strategy behind positioning TAAT™ as a tobacco category product to appeal to legal-aged smokers who could prefer a familiar product format. 

In regards to the article, Setti Coscarella commented, “Obtaining coverage of TAAT™ in a national mainstream news outlet such as Forbes is a tremendous milestone because it demonstrates positive reception and validation of TAAT™ as a company that is gaining momentum in the  $814 billion tobacco industry.

On behalf of the entire team, I can say we are very thankful for Amanda Siebert’s interest in the product and the company, and we hope this coverage helps to bring additional eyeballs of legal-aged smokers to TAAT™.”

The company will be hosting a live Q&A session with Mr. Coscarella on a Facebook Live stream at 9:15 am PST / 12:15 pm EST on Thursday, February 4, 2021. 

TAAT (TAAT) is up 6.54 per cent, trading at C$3.42 at 4 pm EST.

More From The Market Online
Scientific labratory

How a small-cap tech stock is broadening MRI technology 

Nanalysis Scientific (TSXV:NSCI) develops and makes compact MRI and nuclear magnetic resonance devices for clinical, lab and industrial use.

PharmAla Biotech launches educational portal for MDMA

PharmAla Biotech (CSE:MDMA) launches its Prescribers Portal for medical practitioners to learn more about MDMA.

Cancer-fighting pharma stock eyes 2027 regulatory approval

Theralase Technologies (TSXV:TLT), a cancer-fighting pharma stock, expands its team with two clinical research associates.

PharmaDrug-PharmaTher Holdings JV submits clinical, regulatory package

Sairiyo Therapeutics, a PharmaDrug (CSE:PHRX) and PharmaTher Holdings (CSE:PHRM) joint venture, pursues a human clinical study in Australia.